Centogene and Critical Path Institute (C-Path) have signed a Memorandum of Understanding (MOU) on drug development for lysosomal diseases (LDs) and improve the quality of life for LD patients.
The partnership aims to enhance both companies’ capacities in genetic and real-world data (RWD) to expedite the creation of safe and potent therapies for LDs. The collaboration will involve data enrichment for specific LDs, genetic testing services, sample analysis reporting, granting limited access to CENTOGENE's Biodatabank, and shared branding efforts. This agreement aims to combine expertise and resources from both companies to overcome hurdles in LD R&D efforts.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.